arthritis (RA) upregulated the function of T regs . 8 Here, we described a decrease of T regs in B-CLL patients treated with THAL whose therapeutical anti-TNF effect is known. The effects of TNF might be opposite in patients with RA and CLL, indicating that different mechanisms might be involved in the regulation of the T regs function.
We read with interest the study by Bilban et al.,
1 which compared the gene expression profile (GEP) of two groups of B-cell chronic lymphocytic leukemia (CLL), selected for different lipoprotein lipase (LPL) mRNA levels. Several GEP studies have shown that LPL, an essential enzyme of lipid metabolism, is one of the genes most closely associated with unmutated (UM) immunoglobulin variable heavy chain (IGHV) genes in CLL. On these basis, LPL has been proposed as a novel predictor for overall survival and progression in CLL patients. 2 Among 111 genes differentially expressed by CLL with high or low LPL expression, Bilban et al. 1 documented that expression of Septin-10 (SEPT10) significantly correlates with both high LPL mRNA levels and UM IGHV gene status. The authors highlighted also the prognostic value of SEPT10 as a time-to-treatment predictor, with a significant earlier need for therapy occurring in patients with high SEPT10 mRNA levels. 1 We recently reported a comprehensive characterization of IGHV3-21-expressing CLL, a disease subset recognized as a specific poor prognosis category, given its clinical behavior mostly independent of IGHV gene mutation status. 3 In this respect, we and others have demonstrated that IGHV3-21 CLL, although frequently displaying a mutated (M) IGHV gene configuration, has an overall survival similar to poor-prognosis UM CLL. [3] [4] [5] Consistently, GEP studies performed by our group and comparison of IGHV3-21 CLL versus non-IGHV3-21 CLL have identified a restricted number of genes (122 probes corresponding to 115 genes) whose differential expression may explain, at least in part, the clinical aggressiveness of IGHV3-21 CLL. 3 By reviewing the list of the 122 probes differentially expressed by IGHV3-21 CLL, 1 we found SEPT10 among the 62 probes (59 genes) significantly downregulated in this CLL subset.
3 Downregulation of SEPT10 in IGHV3-21 CLL was an unexpected finding, because SEPT10 expression is considered a poor prognostic marker and IGHV3-21 CLL typically has poor clinical outcome.
To investigate this issue in detail, a quantitative real-time PCR (QRT-PCR) procedure was specifically devoted to investigate the expression levels of SEPT10 in highly purified CLL cells from a series of IGHV3-21 (10 cases) and non-IGHV3-21 (19 cases) CLL, with either UM (14 cases) or M (15 cases) IGHV gene configuration (Figure 1a) . Briefly, 50 ng of retro-transcribed DNAse I-treated total RNA was amplified in the presence of 0.5 pmol/ml of primers specific for SEPT10 (sense: 5 0 -GCT AAG GTC AAC GCT GCA AT-3 0 ; antisense: 5 0 -TTT CTC CTT TAC TCG CTG CAC-3 0 ) or b2-microglobulin (b2M), 5 with the following protocol: 10 min at 951C for initial denaturation, 40 cycles of 15 s at 951C, 30 s at 571C (621C for b2M) and 1 min at 721C, followed by final extension at 721C for 5 min. Incorporation of SYBR Green dye into PCR products was monitored in real time with an ABI PRISM 7700 sequence detection system (Applied Biosystems, Foster City, CA, USA). Standard curves (10-fold dilution from 10 1 to 10 À4 attomoles) were prepared for both SEPT10 and the housekeeping gene b2M. Normalized SEPT10 values were obtained by dividing the amounts of SEPT10 by those of b2M, as determined by the respective standard curves. Figure 1a shows the relative expression levels of SEPT10 obtained in UM and M non-IGHV3-21 CLL, as well as in IGHV3-21-expressing cases. As expected, IGHV3-21 CLL was almost exclusively (9/10 cases) represented by CLL with M IGHV gene configuration. Although with a certain degree of case-to-case variation (Figure 1a ), QRT-PCR results revealed that the mean expression level of SEPT10 was significantly higher in UM than in M CLL (P ¼ 0.025 by ttest), irrespective of expression of the IGVH3-21 gene (Figure 1a , inset). Curiously, the sole UM IGHV3-21-expressing CLL expressed negligible SEPT10 levels ( Figure 1a) .
Therefore, overall, QRT-PCR experiments were consistent with GEP results, indicating the lack of SEPT10-specific transcripts in the poor prognosis CLL subset expressing the IGHV3-21 gene. To exclude that this result might be due to an unwanted bias in our CLL cohort, we reanalyzed our GEP data set 3 after withdrawing IGHV3-21-expressing cases, and performed a supervised comparison between poor and good prognosis cases on the remaining non-IGHV3-21 CLL.
For this purpose, we selected 11 UM CLL also expressing the bad prognosticator CD38 in more than 30% of cells, to be compared to 29 cases with M IGHV gene status and expressing CD38 in less than 10% of cells. Bioinformatic analyses were performed by applying the same multi-significance analysis of microarrays (multi-SAM) approach that has been previously employed and that was purposely set up to deal with unbalanced data sets (11 versus 29 samples). 3 This approach consists in a recursive application of SAM so that the lesspopulated UM/CD38 high CLL class (11 cases) was compared with a series of random samplings (1000 samplings), each of them of 11 cases, from the more-populated M/CD38 low CLL class. For each single application of SAM, a list of differentially expressed genes (that is, with adjusted Po10 À3 ) was generated. At the end of 1000 reiterations, each single probe was labeled with a 'score' (list score (LS)) ranging from 0 to 1000 based on the times that this probe was selected by 'multi-SAM' as 'differentially expressed': the higher the score (that is, the number of lists containing a given probe), the higher the 'weight' of this probe as one of those capable of correctly classifying UM/ CD38 high versus M/CD38 low CLL. By using an LS threshold 4500, we selected 146 probes, of which 53 were upregulated and 93 downregulated in UM/CD38 high CLL cells (not shown). Of note, SEPT10 was selected among the best correlated genes upregulated in UM/CD38 high cases. In particular, the two copies present in microarray glass slides 3 for this gene were both selected and showed LS as high as 825 or 964, and median log difference (MLD) of 2.66 and 3.28, respectively (Figure 1b ). For comparison, other genes known to be upregulated in UM and/or CD38 high CLL, including the spastic paraplegia 20 (SPG20) and the activation-induced cytidine deaminase (AICD) genes, were also selected by our analyses (Figure 1b) , indicating that, overall, our GEP data set was in keeping with literature data. 1, 6 Altogether, these studies indicate that SEPT10 expression levels are more likely related to IGHV gene mutations rather than to CLL prognosis. In this regard, the prognostic relevance of SEPT10 underscored by Bilban et al.
1 appeared to be mostly due to its intrinsic characteristic as a surrogate for IGHV gene mutational status. However, the clinical value of SEPT10 expression seems to be strongly limited by its inability to recognize the poor prognosis CLL subset expressing the IGHV3-21 gene, which is known to escape the rule correlating the UM IGHV gene status with poor outcome in CLL. [3] [4] [5] Despite the biased geographical distribution of IGHV3-21-expressing CLL, more frequent in northern than in southern countries, this specific disease subset should not be disregarded, as it has been unequivocally found also in those areas, like the Mediterranean, where its presence was initially questioned. 
Letters to the Editor
The ongoing recognition of several stereotyped combinations of B-cell receptor (BCR), sometimes associated with different prognosis, is gradually shifting the interest of BCR studies from a mere quantitative evaluation of IGHV gene mutational load toward a more complex identification of specific qualitative features of BCR. These include the characterization of IGHV-D-J rearrangements and the association with specific IGK/L chains, which may have, along with pathogenetic implications, both prognostic and therapeutic relevance. 7 The example reported here on SEPT10 expression in CLL mandates the need to integrate studies of novel surrogates for IGHV gene status, whose discovery is nowadays favored by the application of powerful techniques like microarrays, with investigations focusing on their clinical value also in the context of specific IGHV genes. As righteously underscored by Bilban et al., only few of the genes discovered by GEP, namely ZAP-70, have been so far validated for clinical use. 1, 8 In this regard, it is mandatory that this validation includes, along with the correlation with IGHV gene mutational status, the demonstration of its independent clinical value in refining the prognostic assessment of CLL patients. 2 In terms of tumorigenesis, it has been described that Ptc, a gene encoding a protein as the receptor of Shh, behaves as a tumor Abbreviations: AML, acute myeloblastic leukemia other than APL; APL, acute promyelocytic leukemia; B-ALL, B-cell acute lymphoblastic leukemia; B-CLL, B-cell chronic lymphocytic leukemia; MM, multiple myeloma; NA, not available; NK, natural killer cell lymphoma with bone marrow involvement; T-ALL, T-cell acute lymphoblastic leukemia; WM, Waldenstrongs macroglobulinemia.
The results are expressed as number of positive cases/number of total examined cases.
